About Polyplus Transfection
Polyplus Transfection is a Healthcare company based in Illkirch-graffenstaden (France) founded in 2001, and was acquired by Sartorius in March 2023. It operates as a transfection Solutions for Healthcare and Life Sciences organizations. Polyplus Transfection has raised $3.23 million across 2 funding rounds from investors including Sartorius, CIC and Warburg Pincus. Polyplus Transfection has completed 2 acquisitions, including Bio Elpida and Xpress Biologics. Polyplus Transfection offers products and services including FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Polyplus Transfection is a biotechnology company that develops and sells innovative solutions for in vivo, in vitro and ex vivo delivery of nucleic acids in research, bioproduction and therapeutics. Supplies its proprietary range of reagents for the transfection of genes, oligonucleotides and siRNA through a global distributor network for use in clinical trials. Also holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery. Products include - jetPRIME, INTERFERin, FectoPRO, PEIpro for in-vitro; in vivo-jetPEI, cGMP grade in vivo-jetPEI, jetSI 10 mM for in vivo; and others like Zip Nucleic acid (ZNA for Molecular Biology Diagnostics), STICKY SIRNA (for Therapeutic siRNA), OLIGOPLUS and SIRNAPLUS (for Therapeutic cationic Oligonucleotides), Personalized transfection services (for Transfection optimization) and Custom-made products (for in vitro transfection, therapeutics).
- Headquarters Illkirch-graffenstaden, France
- SectorsHealthcare
- Website polyplus-transfection.com
- Social LinkedIn X YouTube
- Acquired by Sartorius (Mar 2023)
- Total Equity Funding$3.23M (USD)
in 2 rounds
- Latest Funding Round$3.23M (USD), Series A
Jan 2011
- InvestorsSartorius
& 9 more
- Investments & AcquisitionsBio Elpida
& 1 more
- Acquired by
Products & Services of Polyplus Transfection
Polyplus Transfection offers a comprehensive portfolio of products and services, including FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS.
For large scale rAAV manufacturing processes
Leader for viral vector production in various scales
For in vivo mRNA delivery using lipid nanoparticles
For high-yield protein expression in cell systems
For efficient DNA transfection in hard-to-transfect cells
Apps and channels of Polyplus Transfection
its YouTube channel Polyplus has 502 subscribers and 21 videos.
Videos from Polyplus Transfection
The most watched videos on Polyplus Transfection's YouTube channel, Polyplus (502 subscribers). Click a video to play it here.
More on Polyplus.
Funding Insights of Polyplus Transfection
Polyplus Transfection has successfully raised a total of $3.23M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.23 million completed in January 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.23M
- Total Rounds 2
- Last Round Series A — $3.23M
- First Round $1.78M
(Dec 2009)
- Investors Count 7
All 2 funding rounds of Polyplus Transfection with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2011 | $3.23M | Series A | – | – | |
| Dec 2009 | $1.78M | Debt – Convertible | – | – |
10 investors in total: 10 institutional.
Investors in Polyplus Transfection
Polyplus Transfection has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Sartorius, CIC and Warburg Pincus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth and acquisition investments are managed by Credit Mutuel Equity. | – | creditmutuel-equity.eu | Paris, France | |
- | – | alsaceinterregioondsdinvestissement.tcc.mode | - | |
- | – | sudinnova.tcc.mode | - | |
Healthcare industries are funded and supported globally by ARCHIMED. | – | archimed.group | Lyon, France | |
Multi-stage private equity investments are pursued across diverse sectors. | 1966 | warburgpincus.com | New York, United States | |
- | – | banquedevizille.fr | - | |
Manages diversified investment portfolios across various asset classes. | 2010 | promelys.com | France | |
Commercial banking services are provided to retail and corporate clients. | 1859 | cic.fr | Paris, France | |
- | – | avenirfinance.fr | - | |
Laboratory and biopharmaceutical equipment is developed for production processes. | 1870 | sartorius.com | Gottingen, Germany |
Investor details for Polyplus Transfection
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Polyplus Transfection
Polyplus Transfection has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bio Elpida and Xpress Biologics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Bio Elpida, a Biotechnology Contract Manufacturing Company for pre-clinical and clinical development of cell therapy products and bio-products | bio-elpida.com | Lyon, France | 2009 | Dec 2022 | •••• | |
CRO offering recombinant protein and antibody related services for preclinical and clinical applications | xpress-biologics.com | Liege, Belgium | 2014 | Dec 2022 | •••• |
Complete acquisition details for Polyplus Transfection
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Polyplus Transfection
8 dated milestones of Polyplus Transfection across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Polyplus Transfection is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Series A, of $3.2M.
- Exit Acquired by ARCHIMED.
- Exit Acquired by Warburg Pincus.
- Acquisition Acquires Xpress Biologics.
- Acquisition Acquires Bio Elpida.
- Exit Acquired by Sartorius.
Competitors of Polyplus Transfection
Polyplus Transfection has 10 listed competitors in our database, 9 of them funded. They include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Polyplus Transfection
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Polyplus Transfection
Websites that share an audience with Polyplus Transfection (polyplus-transfection.com).
Websites whose visitors overlap most with Polyplus Transfection. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocat.com | 100% | 37.9K | #866,969 | View details | |
| biocellchallenge.com | 96% | – | – | View details | |
tissue-array.com | tissue-array.com | 87% | – | #14,306,137 | – |
immunometrics.co.uk | immunometrics.co.uk | 87% | – | – | – |
| larova.com | 87% | 1.2K | #12,350,883 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Polyplus Transfection
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Polyplus Transfection (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Polyplus Transfection
Complete news archive for Polyplus Transfection
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Polyplus Transfection
Polyplus Transfection was founded in 2001 and raised its 1st funding round 8 years after it was founded.
Polyplus Transfection is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
Polyplus Transfection is a funded company, having raised a total of $3.23M across 2 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $1.78M, raised on Dec 2009.
Polyplus Transfection is a biotechnology company that develops and sells innovative solutions for in vivo, in vitro and ex vivo delivery of nucleic acids in research, bioproduction and therapeutics. Supplies its proprietary range of reagents for the transfection of genes, oligonucleotides and siRNA through a global distributor network for use in clinical trials. Also holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery. Products include - jetPRIME, INTERFERin, FectoPRO, PEIpro for in-vitro; in vivo-jetPEI, cGMP grade in vivo-jetPEI, jetSI 10 mM for in vivo; and others like Zip Nucleic acid (ZNA for Molecular Biology Diagnostics), STICKY SIRNA (for Therapeutic siRNA), OLIGOPLUS and SIRNAPLUS (for Therapeutic cationic Oligonucleotides), Personalized transfection services (for Transfection optimization) and Custom-made products (for in vitro transfection, therapeutics).
Polyplus Transfection's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Polyplus Transfection offers FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS.
Polyplus Transfection has made 2 acquisitions, including Bio Elpida, and Xpress Biologics.
Polyplus Transfection has 10 investors. Key investors include Sartorius, CIC, Warburg Pincus, Crédit Mutuel Equity, and Banque de Vizille.
Yes. Polyplus Transfection was acquired by Sartorius in March 2023.